hh.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development
Dept. of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Halmstad University, School of Business, Engineering and Science, The Rydberg Laboratory for Applied Sciences (RLAS). Dept. of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
2016 (English)In: Immunopharmacology and immunotoxicology, ISSN 0892-3973, E-ISSN 1532-2513, Vol. 38, no 1, 2-13 p.Article in journal (Refereed) Published
Abstract [en]

Development of novel drugs for treatment of chronic inflammatory diseases is to a large extent dependent on the availability of good experimental in vivo models in order to perform preclinical tests of new drugs and for the identification of novel drug targets. Here, we review a number of existing rodent models for Rheumatoid Arthritis in the context of how these models have been utilized for developing established therapy in Rheumatoid Arthritis and, furthermore, the present use of animal models for studies of novel drug candidates. We have studied the literature in the field for the use of in vivo models during development of anti-rheumatic drugs; from Methotrexate to various antibody treatments, to novel drugs that are, or have recently been, in clinical trials. For novel drugs, we have explored websites for clinical trials. Although a single Rheumatoid Arthritis in vivo model cannot mirror the complexity of disease development, there exist a number of good animal models for Rheumatoid Arthritis, each defining some parts in disease development, which are useful for studies of drug response. We find that many of the established drugs were not tested in in vivo models before being used in the clinic, but rather animal models have been subsequently used to find mechanisms for efficacy. Finally, we report a number of novel drugs, tested in preclinical in vivo models, presently in clinical trials. © 2016 Taylor and Francis.

Place, publisher, year, edition, pages
Philadelphia, PA: Taylor & Francis, 2016. Vol. 38, no 1, 2-13 p.
Keyword [en]
Anti-rheumatic drugs, biological agents, DMARDs, experimental arthritis models, joint inflammation
National Category
Rheumatology and Autoimmunity
Identifiers
URN: urn:nbn:se:hh:diva-33669DOI: 10.3109/08923973.2015.1125917ISI: 000371012900002PubMedID: 26769136ScopusID: 2-s2.0-84957438985OAI: oai:DiVA.org:hh-33669DiVA: diva2:1086919
Note

Funding: Danish Association for Rheumatism

Available from: 2017-04-04 Created: 2017-04-04 Last updated: 2017-04-05Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Andersson, Åsa
By organisation
The Rydberg Laboratory for Applied Sciences (RLAS)
In the same journal
Immunopharmacology and immunotoxicology
Rheumatology and Autoimmunity

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 6 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf